Skip to main content
. Author manuscript; available in PMC: 2011 May 3.
Published in final edited form as: J Immunol. 2010 Mar 15;184(8):4185–4195. doi: 10.4049/jimmunol.0903420

FIGURE 6.

FIGURE 6

Transfection of Siglec-5 into primary human T lymphocytes leads to decreased proliferation. Freshly isolated human PBMCs were labeled with CFSE and nucleofected with Siglec-5 expression plasmid. A, Siglec-5 expression in nucleofected cells was detected by flow cytometry using an anti–siglec-5 Ab. B, Cell proliferation was analyzed by comparing CFSE content in cells nucleofected with Siglec-5 plasmid versus cells nucleofected with no plasmid (Neg control). C, CFSE profile of cells within the population of nucleofected cells that were expressing Siglec-5, compared with the CFSE profile of cells within the same population that were not expressing Siglec-5. Data shown are representative of two independent experiments.

HHS Vulnerability Disclosure